Mark Joseph Enyedy
Net Worth
Last updated:
What is Mark Joseph Enyedy net worth?
The estimated net worth of Mr. Mark Joseph Enyedy is at least $63,921,155 as of 5 Feb 2024. He has earned $53,031,155 from insider trading and has received compensation worth at least $10,890,000 in ImmunoGen, Inc..
What is the salary of Mark Joseph Enyedy?
Mr. Mark Joseph Enyedy salary is $1,210,000 per year as Pres, Chief Executive Officer & Director in ImmunoGen, Inc..
How old is Mark Joseph Enyedy?
Mr. Mark Joseph Enyedy is 61 years old, born in 1964.
What stocks does Mark Joseph Enyedy currently own?
As insider, Mr. Mark Joseph Enyedy owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ImmunoGen, Inc. (IMGN) | Pres, Chief Executive Officer & Director | 584,397 | $0 | $0 |
What does ImmunoGen, Inc. do?
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Mark Joseph Enyedy insider trading
ImmunoGen, Inc.
Mr. Mark Joseph Enyedy has made 8 insider trades between 2016-2024, according to the Form 4 filled with the SEC. Most recently he sold 20,107 units of IMGN stock worth $588,733 on 5 Feb 2024.
The largest trade he's ever made was exercising 1,082,240 units of IMGN stock on 4 Aug 2023. As of 5 Feb 2024 he still owns at least 584,397 units of IMGN stock.
ImmunoGen key executives
ImmunoGen, Inc. executives and other stock owners filed with the SEC:
- Dr. Anna Berkenblit (55) Senior Vice President & Chief Medical Officer
- Dr. Theresa G. Wingrove (67) Senior Vice President of Regulatory Affairs & Quality
- Mr. Mark Joseph Enyedy (61) Pres, Chief Executive Officer & Director
- Ms. Stacy A. Coen (54) Senior Vice President & Chief Bus. Officer
- Ms. Susan Altschuller Ph.D. (43) Senior Vice President & Chief Financial Officer